Analyzing Reliv’ International (OTCMKTS:RELV) & AEON Biopharma (NASDAQ:AEON)

Reliv’ International (OTCMKTS:RELV) and AEON Biopharma (NASDAQ:AEON) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Volatility & Risk

Reliv’ International has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Institutional & Insider Ownership

7.7% of Reliv’ International shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 30.0% of Reliv’ International shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Reliv’ International and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reliv’ International	-0.61%	-1.89%	-1.31%
AEON Biopharma	N/A	N/A	-994.63%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Reliv’ International and AEON Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reliv’ International	0	0	0	0	0.00
AEON Biopharma	0	1	1	1	3.00

Valuation and Earnings

This table compares Reliv’ International and AEON Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reliv’ International	$35.06 million	0.09	-$440,000.00	($0.09)	-20.33
AEON Biopharma	N/A	N/A	-$36.63 million	($5.00)	-0.05

Reliv’ International has higher revenue and earnings than AEON Biopharma. Reliv’ International is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

AEON Biopharma beats Reliv’ International on 8 of the 13 factors compared between the two stocks.

About Reliv’ International

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.